Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.

Tiberi S, du Plessis N, Walzl G, Vjecha MJ, Rao M, Ntoumi F, Mfinanga S, Kapata N, Mwaba P, McHugh TD, Ippolito G, Migliori GB, Maeurer MJ, Zumla A.

Lancet Infect Dis. 2018 Jul;18(7):e183-e198. doi: 10.1016/S1473-3099(18)30110-5. Epub 2018 Mar 23. Review. Erratum in: Lancet Infect Dis. 2018 Apr 27;:.

PMID:
29580819
2.

Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.

Wallis RS, Maeurer M, Mwaba P, Chakaya J, Rustomjee R, Migliori GB, Marais B, Schito M, Churchyard G, Swaminathan S, Hoelscher M, Zumla A.

Lancet Infect Dis. 2016 Apr;16(4):e34-46. doi: 10.1016/S1473-3099(16)00070-0. Review.

PMID:
27036358
3.

Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp Debates.

Zumla A, Maeurer M; Host-Directed Therapies Network (HDT-NET) Consortium.

Clin Infect Dis. 2015 Nov 1;61(9):1432-8. doi: 10.1093/cid/civ631. Epub 2015 Jul 28.

4.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
5.

Tuberculosis.

Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, Knight G, Murray M, Nardell E, Rubin E, Salomon J, Vassall A, Volchenkov G, White R, Wilson D, Yadav P.

In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11.

6.

New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.

Zumla AI, Gillespie SH, Hoelscher M, Philips PP, Cole ST, Abubakar I, McHugh TD, Schito M, Maeurer M, Nunn AJ.

Lancet Infect Dis. 2014 Apr;14(4):327-40. doi: 10.1016/S1473-3099(13)70328-1. Review.

PMID:
24670627
7.

Pipeline of drugs for related diseases: tuberculosis.

Dooley KE, Nuermberger EL, Diacon AH.

Curr Opin HIV AIDS. 2013 Nov;8(6):579-85. doi: 10.1097/COH.0000000000000009. Review.

8.

The challenge of the new tuberculosis drugs.

Tiberi S, Buchanan R, Caminero JA, Centis R, Arbex MA, Salazar M, Potter J, Migliori GB.

Presse Med. 2017 Mar;46(2 Pt 2):e41-e51. doi: 10.1016/j.lpm.2017.01.016. Epub 2017 Feb 28. Review. French.

PMID:
28256383
9.

Improving treatment outcomes for MDR-TB - Novel host-directed therapies and personalised medicine of the future.

Rao M, Ippolito G, Mfinanga S, Ntoumi F, Yeboah-Manu D, Vilaplana C, Zumla A, Maeurer M.

Int J Infect Dis. 2019 Mar;80S:S62-S67. doi: 10.1016/j.ijid.2019.01.039. Epub 2019 Jan 24.

10.

Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease.

Palucci I, Delogu G.

Chemotherapy. 2018;63(3):172-180. doi: 10.1159/000490478. Epub 2018 Jul 20. Review.

11.

Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis.

Zumla A, Rao M, Dodoo E, Maeurer M.

BMC Med. 2016 Jun 15;14:89. doi: 10.1186/s12916-016-0635-1. Review.

12.

Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies.

Zumla A, Chakaya J, Centis R, D'Ambrosio L, Mwaba P, Bates M, Kapata N, Nyirenda T, Chanda D, Mfinanga S, Hoelscher M, Maeurer M, Migliori GB.

Lancet Respir Med. 2015 Mar;3(3):220-34. doi: 10.1016/S2213-2600(15)00063-6. Epub 2015 Mar 9. Review.

PMID:
25773212
13.

Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance.

Lohrasbi V, Talebi M, Bialvaei AZ, Fattorini L, Drancourt M, Heidary M, Darban-Sarokhalil D.

Tuberculosis (Edinb). 2018 Mar;109:17-27. doi: 10.1016/j.tube.2017.12.002. Epub 2017 Dec 9. Review.

PMID:
29559117
14.

Synthetic investigational new drugs for the treatment of tuberculosis.

Kwon YS, Koh WJ.

Expert Opin Investig Drugs. 2016;25(2):183-93. doi: 10.1517/13543784.2016.1121993. Epub 2015 Dec 14. Review.

PMID:
26576631
15.

Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).

Liu Y, Matsumoto M, Ishida H, Ohguro K, Yoshitake M, Gupta R, Geiter L, Hafkin J.

Tuberculosis (Edinb). 2018 Jul;111:20-30. doi: 10.1016/j.tube.2018.04.008. Epub 2018 May 3. Review.

PMID:
30029909
16.

Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment.

Lange C, Chesov D, Heyckendorf J, Leung CC, Udwadia Z, Dheda K.

Respirology. 2018 Jul;23(7):656-673. doi: 10.1111/resp.13304. Epub 2018 Apr 11. Review.

17.
18.

News on therapeutic management of MDR-tuberculosis: a literature review.

Barthod L, Lopez JG, Curti C, Bornet C, Roche M, Montana M, Vanelle P.

J Chemother. 2018 Feb;30(1):1-15. doi: 10.1080/1120009X.2017.1338845. Epub 2017 Jun 26. Review.

PMID:
28651480
19.

Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.

Kwon YS, Jeong BH, Koh WJ.

Expert Opin Pharmacother. 2015 Feb;16(2):253-61. doi: 10.1517/14656566.2015.973853. Epub 2014 Oct 18. Review.

PMID:
25327169
20.

[Recent progress in mycobacteriology].

Okada M, Kobayashi K.

Kekkaku. 2007 Oct;82(10):783-99. Japanese.

PMID:
18018602

Supplemental Content

Support Center